EMERYVILLE, Calif., Aug. 20, 2012 (GLOBE NEWSWIRE) -- NovaBay ® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide ® compounds for the local non-systemic treatment and prevention of infections, today announced that Dr. Ron Najafi, Chief Executive Officer, will present at the 2012 Southern California Investor Conference, held August 30, 2012, in Newport Beach, California. Dr. Najafi and Tom Paulson, Chief Financial Officer, will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
|Event||Southern California Investor Conference|
|Date||Thursday, August 30, 2012|
|Time||8:30 am PT|
|Place||Marriott Hotel-Newport Beach, Newport Beach, CA|
- Dermatology – Partnered with Galderma, a leading dermatology company, to develop a formulation of NVC-422 for treatment of highly contagious skin infection, impetigo, caused primarily by S. aureus and Group A Beta-hemolytic streptococci. A major global Phase 2b clinical study is planned for 2012.
- Ophthalmology – NovaBay is developing an eye drop formulation of NVC-422 for treating adenoviral conjunctivitis. Enrollment into a global Phase 2b clinical study has begun with top-line data expected in the first half of 2013.
- Urology – NovaBay's urinary catheter irrigation solution containing NVC-422 is currently enrolling patients in its Phase 2 proof-of-concept clinical studies, with the goal of reducing the incidence of urinary catheter blockage and encrustation (UCBE) and associated urinary tract infections. The Company reported positive data from Part A of this study and expects to announce top-line results from Part B later in 2012.
- Like us on Facebook
- Follow us on Twitter
- Connect with NovaBay on LinkedIn
- Join us on Google+
- Visit NovaBay's Website
CONTACT: Investors: NovaBay Pharmaceuticals, Inc. Thomas J. Paulson Chief Financial Officer (510) 899-8809 firstname.lastname@example.org Investors and Media: The Ruth Group Stephanie Carrington / Nicole Greenbaum (Investors) (646) 536-7017 / 7009 email@example.com / firstname.lastname@example.org Victoria Aguiar (Media) (646) 536-7013 email@example.com